載入中
NYSEHealthcareDrug Manufacturers - General
最新資料
US$38.64
+US$0.46 · +1.20%
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
前收盤價
US$38.64
+US$0.46 · +1.20%
盤中時間採用ET。市場資料可能有所延遲。
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
日內區間
目前US$38.64
52週區間
目前US$38.64
盤中時間採用ET。市場資料可能有所延遲。
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
日內區間
目前US$38.64
52週區間
目前US$38.64
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年9月20日 | 2:1 | — | — |
股票分割 | 2014年1月9日 | 5:1 | — | — |
股票分割 | 2007年12月17日 | 2:1 | — | — |
股票分割 | 2001年4月11日 | 5:2 | — | — |
股票分割 | 1994年4月18日 | 4:1 | — | — |
已生效 2023年9月20日
2:1
已生效 2014年1月9日
5:1
已生效 2007年12月17日
2:1
已生效 2001年4月11日
5:2
已生效 1994年4月18日
4:1
報告持有此股票曝險的交易所交易基金。
VanEck Pharmaceutical ETFPPH5792.05萬5.65%10.37億 USD0.36%US$110.49+1.20%
Avantis International Equity ETFAVDE5312.99萬0.28%192.24億 USD0.23%US$89.80+0.58%
First Trust WCM International Equity ETFWCMI3157.63萬1.51%20.87億 USD0.85%US$19.05+1.06%
Fidelity Enhanced International ETFFENI1792.88萬0.16%114.7億 USD0.28%US$39.69+0.43%
Invesco International Dividend Achievers ETFPID1711.98萬2.00%8.58億 USD0.53%US$21.7117+0.10%
Hartford Multifactor Developed Markets (ex-US) ETFRODM1119.79萬0.70%16.15億 USD0.29%US$40.82+0.25%
Avantis International Large Cap Value ETFAVIV1108.75萬0.55%20.24億 USD0.25%US$79.00+0.34%
ActivePassive International Equity ETFAPIE842.69萬0.74%11.41億 USD0.45%US$38.56+0.65%VanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEFirst Trust WCM International Equity ETFWCMIFidelity Enhanced International ETFFENIInvesco International Dividend Achievers ETFPIDHartford Multifactor Developed Markets (ex-US) ETFRODMAvantis International Large Cap Value ETFAVIVActivePassive International Equity ETFAPIEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
